West Pharmaceutical stock price target raised to $390 from $350 at Evercore ISI

Investing.com - Evercore ISI raised its price target on West Pharmaceutical (NYSE:WST) to $390.00 from $350.00 on Thursday, while maintaining an Outperform rating on the stock. The company, currently valued at $22.2 billion, trades at $309.03 per share and maintains a "GOOD" financial health score according to InvestingPro analysis.

The research firm cited that its "bull thesis is coming to life" with the High-Value Product (HVP) Components thesis playing out as expected.

Evercore ISI highlighted a "strong setup into 2026 with upside potential" in High-Value Components (HVCs), which forms the core of its investment case for West Pharmaceutical.

The new price target implies approximately 47 times 2026 price-to-earnings ratio and about 32 times EBITDA, according to the research note.

Evercore ISI referenced an earlier note from March that outlined a bull thesis with more than 60% upside potential for West Pharmaceutical, stating that this outlook is "increasingly coming into focus."

In other recent news, West Pharmaceutical Services Inc. reported strong third-quarter earnings for 2025, surpassing market expectations. The company achieved an adjusted earnings per share of $1.96, which exceeded the forecasted $1.69. Additionally, West Pharmaceutical reported revenue of $805 million, outperforming the predicted $786.33 million. These results contributed to the company raising its full-year revenue guidance, now projecting between $3.06 billion and $3.07 billion. This development highlights the company’s positive financial performance in the recent quarter. The earnings surprise was 15.98%, reflecting a significant deviation from analyst estimates. The company’s financial results have drawn attention from investors, marking a notable period of growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.